Unlike consumer-facing drugs, many cancer therapies have names derived from their scientific mechanism of action. This is a deliberate strategy to communicate the drug's uniqueness and resonate with the true target audience: oncologists who understand the science.
The iconic name 'Viagra' was created for a prostate drug to evoke a "vigorous stream." When Pfizer developed a drug for erectile dysfunction, it repurposed the pre-existing, "banked" name, showing how companies strategically reuse branding assets for a better fit.
Professional namers create detailed, emotional backstories to guide creativity. For the insulin 'Toujeo,' the namer developed a romantic narrative about young diabetics gaining spontaneity, which led to a name derived from the Haitian Creole word for "always."
The 1988 launch of Prozac marked a major shift in pharmaceutical branding. Its name was a non-descriptive "empty vessel" designed for marketing impact ('pro' for positive, 'zac' for energy), moving away from names that explained a drug's function.
The FDA's strict guidelines against look-alike/sound-alike names (to prevent prescription errors) and names that over-promise a cure are the primary drivers behind the seemingly strange, unique, and often sci-fi-sounding spellings of modern pharmaceutical brands.
To find a single viable drug name, agencies like Brand Institute generate an initial list of 300 to 500 concepts. This massive brainstorming effort highlights the scale of the creative process, with the vast majority of ideas being rejected long before regulatory review.
To prevent errors from illegible handwriting, the FDA favors drug names with a varied visual shape, created by using letters that ascend (b, d, h) and descend (g, p, y). This typographical safety consideration is a key, non-obvious factor in a name's approval.